Academic Sponsors / Collaborators
Interaction Checker
We have produced various materials in PDF format to aid the use of experimental agents in the treatment of COVID-19.
These resources are freely available and the Liverpool Drug Interactions Group would like to encourage the dissemination (with an appropriate acknowledgement) of this drug-drug interaction information for non-commercial use. If referencing these Prescribing Resources, it is important to include the publication date since these resources are updated as new data come to light. Please cite as: [Prescribing Resource Title], [PDF Publication Date], University of Liverpool, available from www.covid19-druginteractions.org, [accession date].
UPDATED – Baricitinib and ruxolitinib added as COVID-19 immune therapies.
Details of the nature of drug interactions with experimental COVID-19 therapies and many comedication classes are given in this PDF.
Updated 23 June 2020
UPDATED – Baricitinib and ruxolitinib added as COVID-19 immune therapies.
Details of the nature of drug interactions with experimental COVID-19 therapies and many comedication classes are given in this PDF.
Updated 17 June 2020
UPDATED – Baricitinib and ruxolitinib added as COVID-19 immune therapies
A summary of interactions with experimental COVID-19 antiviral therapies and over 500 comedications are given in this PDF.
Updated 23 June 2020
UPDATED – Baricitinib and ruxolitinib added as COVID-19 immune therapies
A summary of interactions with experimental COVID-19 immune therapies and over 500 comedications are given in this PDF.
Updated 17 June 2020
NEW
Details of dose modifications of experimental COVID-19 therapies which may be required for patients with renal impairment are given in this PDF.
Updated 17 June 2020
NEW
Details of dose modifications of experimental COVID-19 therapies which may be required for patients with hepatic impairment are given in this PDF.
Updated 17 June 2020
UPDATED - Baricitinib and ruxolitinib added as COVID-19 immune therapies.
Advice for administering experimental COVID-19 therapies to patients who cannot swallow is given in this PDF.
Updated 17 June 2020
UPDATED - information added for baricitinib and ruxolitinib.
This document explains how we have evaluated the drug-drug interaction risk of the experimental COVID-19 therapies and gives details of their metabolism, interaction potential and cardiac effects.
Updated 17 June 2020
